Patents Assigned to INSTITUT JEAN PAOLI & IRENE CALMETTES
  • Compositions useful in the diagnostic of latently infected
    Patent number: 10067147
    Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: September 4, 2018
    Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), Conicet (Consejo Nacional de Investigaciones Cientificas y Tecnicas, Institut Jean Paoli & Irene Calmettes, Universite d'Aix-Marseille, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Juan Iovanna, Virginia Pasquinelli, Maria Madgalena Gherardi, Hector Eduardo Chuluyan, Ana Inès Rovetta, Delfina Pena, Véronica Edith Garcia
  • Antagonist of the BTLA/HVEM interaction for use in therapy
    Patent number: 10005839
    Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: June 26, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Daniel Olive, Christine Pasero, Julie Gertner-Dardenne
  • Antibodies directed against ICOS and uses thereof
    Patent number: 9975950
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: May 22, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • COMPOSITIONS USEFUL IN THE DIAGNOSTIC OF LATENTLY INFECTED MYCOBACTERIUM TUBERCULOSIS
    Publication number: 20170242038
    Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
    Type: Application
    Filed: August 28, 2015
    Publication date: August 24, 2017
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), CONICET (CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Juan IOVANNA, Virginia PASQUINELLI, Maria Madgalena GHERARDI, Hector Eduardo CHULUYAN, Ana Inès ROVETTA, Delfina PENA, Véronica Edith GARCIA
  • Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
    Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • Hydrophobically modified antisense oligonucleotides comprising a ketal group
    Patent number: 9701962
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 11, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE BORDEAUX, UNIVERSITE D 'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Antibodies directed against ICOS and uses thereof
    Patent number: 9676852
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: June 13, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Methods for selecting binders by phage display and masked selection
    Patent number: 9605257
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 28, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • NOVEL ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20160331818
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 17, 2016
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc LOPEZ, Daniel OLIVE
  • Antibodies directed against ICOS and uses thereof
    Patent number: 9376493
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 28, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Mediacale), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE CLAUDE BERNARD, CENTRE LEON BERARD
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Antigen peptide and uses thereof
    Patent number: 9266922
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: February 23, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Institut Jean Paoli & Irene Calmettes
    Inventors: Marc Lopez, Daniel Olive
  • NOVEL ANTIGEN PEPTIDE AND USES THEREOF
    Publication number: 20140178394
    Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: June 26, 2014
    Applicants: UNIVERSITE D'AIX MARSEILLE, INSERM (Insititut Nationa de la Sante et de la Rec Recherche Medicals), INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc Lopez, Daniel Olive
  • Antibodies Directed Against ICOS and Uses Thereof
    Publication number: 20140086923
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicants: INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante et de la Recherche Medicale, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD - LYON 1
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive